Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
STAA Stock Forecast 2025-2026
$23.99
Current Price
$1.18B
Market Cap
Buy 1
Hold 9
Sell 0
Wall St Analyst Ratings
Distance to STAA Price Targets
+16.7%
To High Target of $28.00
+16.7%
To Median Target of $28.00
-33.3%
To Low Target of $16.00
STAA Price Momentum
-9.8%
1 Week Change
-12.4%
1 Month Change
-5.0%
1 Year Change
-1.2%
Year-to-Date Change
-22.1%
From 52W High of $30.81
+77.7%
From 52W Low of $13.50
📊 TOP ANALYST CALLS
Did STAA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if STAAR Surgical is one of their latest high-conviction picks.
Latest STAA Stock Price Targets & Analyst Predictions
Based on our analysis of 17 Wall Street analysts, STAA has a neutral consensus with a median price target of $28.00 (ranging from $16.00 to $28.00). The overall analyst rating is Buy (6.4/10). Currently trading at $23.99, the median forecast implies a 16.7% upside. This outlook is supported by 1 Buy, 9 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Thomas Stephan at Stifel, projecting a 16.7% upside. Conversely, the most conservative target is provided by Matt O'Brien at Piper Sandler, suggesting a 33.3% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
STAA Analyst Ratings
1
Buy
9
Hold
0
Sell
STAA Price Target Range
Low
$16.00
Average
$28.00
High
$28.00
Current: $23.99
Latest STAA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for STAA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Aug 7, 2025 | Stifel | Thomas Stephan | Hold | Downgrade | $28.00 |
| Aug 6, 2025 | Canaccord Genuity | Jon Young | Hold | Maintains | $28.00 |
| Aug 5, 2025 | Sidoti & Co. | James Sidoti | Neutral | Downgrade | $28.00 |
| Jul 16, 2025 | Mizuho | Anthony Petrone | Neutral | Maintains | $18.00 |
| May 27, 2025 | Canaccord Genuity | Jon Young | Hold | Maintains | $20.00 |
| May 21, 2025 | Needham | David Saxon | Hold | Reiterates | $N/A |
| May 8, 2025 | Canaccord Genuity | Jon Young | Hold | Maintains | $20.00 |
| Apr 21, 2025 | Wells Fargo | Equal-Weight | Initiates | $17.00 | |
| Mar 18, 2025 | Stephens & Co. | Mason Carrico | Equal-Weight | Reiterates | $17.00 |
| Feb 27, 2025 | Needham | David Saxon | Hold | Reiterates | $N/A |
| Feb 13, 2025 | Canaccord Genuity | Jon Young | Hold | Maintains | $17.00 |
| Feb 12, 2025 | Stephens & Co. | Mason Carrico | Equal-Weight | Reiterates | $28.00 |
| Feb 12, 2025 | Stifel | Thomas Stephan | Buy | Maintains | $20.00 |
| Feb 12, 2025 | Piper Sandler | Matt O'Brien | Neutral | Maintains | $16.00 |
| Feb 12, 2025 | Needham | David Saxon | Hold | Reiterates | $N/A |
| Feb 12, 2025 | William Blair | Margaret Kaczor | Market Perform | Downgrade | $N/A |
| Jan 7, 2025 | Needham | David Saxon | Hold | Reiterates | $N/A |
| Dec 9, 2024 | Canaccord Genuity | Jon Young | Hold | Maintains | $28.00 |
| Nov 1, 2024 | Canaccord Genuity | Jon Young | Hold | Maintains | $31.00 |
| Oct 31, 2024 | Needham | David Saxon | Hold | Reiterates | $N/A |
Staar Surgical Company (STAA) Competitors
The following stocks are similar to STAAR Surgical based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Staar Surgical Company (STAA) Financial Data
Staar Surgical Company has a market capitalization of $1.18B with a P/E ratio of 49.7x. The company generates $230.59M in trailing twelve-month revenue with a -41.8% profit margin.
Revenue growth is +6.9% quarter-over-quarter, while maintaining an operating margin of +25.9% and return on equity of -24.6%.
Valuation Metrics
Market Cap
$1.18B
Enterprise Value
$1.11B
P/E Ratio
49.7x
PEG Ratio
-5.0x
Price/Sales
5.4x
Growth & Margins
Revenue Growth (YoY)
+6.9%
Gross Margin
+82.2%
Operating Margin
+25.9%
Net Margin
-41.8%
EPS Growth
-11.0%
Financial Health
Cash/Price Ratio
+16.1%
Current Ratio
5.2x
Debt/Equity
11.1x
ROE
-24.6%
ROA
-7.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Staar Surgical Company (STAA) Business Model
About Staar Surgical Company
What They Do
Develops implantable lenses for vision correction.
Business Model
Staar Surgical Company generates revenue primarily through the development, manufacture, and sale of its Implantable Collamer Lens (ICL) and other implantable lenses used in refractive surgery. By focusing on innovative and effective solutions for vision defects, the company effectively serves both ophthalmologists and patients, establishing a strong market presence in the ophthalmology sector.
Additional Information
Headquartered in California, Staar Surgical has a global reach, impacting the eye care industry significantly. The company is committed to continuous research and development to enhance its product offerings and maintain its leadership in advanced eye care solutions, aiming to improve the quality of life for individuals with visual impairments.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
1,157
CEO
Mr. Stephen C. Farrell CFA
Country
United States
IPO Year
1992
Website
www.staar.comStaar Surgical Company (STAA) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
What Makes Staar Surgical (STAA) a New Buy Stock
Staar Surgical (STAA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Dec 09, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Staar Surgical (STAA) has been upgraded to a Zacks Rank #2 (Buy), indicating improved earnings outlook which may boost the stock price in the near term.
Why It Matters
Staar Surgical's upgrade to a Zacks Rank #2 signals positive earnings outlook, likely boosting investor confidence and potentially increasing the stock's value.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Alcon has announced an amended merger agreement with STAAR Surgical.
Why It Matters
Alcon's amended merger agreement with STAAR Surgical may impact stock valuations, competitive positioning, and market dynamics in the ophthalmic sector, influencing investor strategies.
Source: Business Wire
Market Sentiment:
Neutral
Broadwood Partners Responds to Alcon's Increase to Proposed Acquisition Price of STAAR Surgical
1 day ago
Quick Summary
Broadwood Partners, holding 30.2% of STAAR Surgical, opposes the amended acquisition terms by Alcon Inc., signaling potential challenges for the deal's approval.
Why It Matters
Broadwood's opposition to Alcon's acquisition of STAAR could indicate potential volatility in STAAR's stock price and affect shareholder sentiment, influencing investment decisions.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
STAAR Surgical's go-shop period under its amended merger agreement with Alcon expired on December 6, 2025, with no proposals received.
Why It Matters
STAAR Surgical's go-shop period has ended without competing offers, solidifying its merger with Alcon. This could stabilize STAAR's stock and streamline future growth prospects.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Egan-Jones Ratings has recommended STAAR Surgical shareholders vote "AGAINST" Alcon's proposed acquisition. This follows STAAR's recent completion of a 30-day go-shop period.
Why It Matters
Egan-Jones' recommendation against the STAAR-Alcon acquisition signals potential instability and investor dissent, impacting share prices and future corporate strategies.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Broadwood Partners, holding 30.2% of STAAR Surgical's shares, opposes STAAR's sale to Alcon, criticizing the unchanged transaction terms after what they view as a flawed process.
Why It Matters
Broadwood's opposition to STAAR's sale to Alcon may signal potential instability or volatility for STAAR's stock, impacting investor confidence and future valuations.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About STAA Stock
What is Staar Surgical Company's (STAA) stock forecast for 2026?
Based on our analysis of 17 Wall Street analysts, Staar Surgical Company (STAA) has a median price target of $28.00. The highest price target is $28.00 and the lowest is $16.00.
Is STAA stock a good investment in 2026?
According to current analyst ratings, STAA has 1 Buy ratings, 9 Hold ratings, and 0 Sell ratings. The stock is currently trading at $23.99. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for STAA stock?
Wall Street analysts predict STAA stock could reach $28.00 in the next 12 months. This represents a 16.7% increase from the current price of $23.99. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Staar Surgical Company's business model?
Staar Surgical Company generates revenue primarily through the development, manufacture, and sale of its Implantable Collamer Lens (ICL) and other implantable lenses used in refractive surgery. By focusing on innovative and effective solutions for vision defects, the company effectively serves both ophthalmologists and patients, establishing a strong market presence in the ophthalmology sector.
What is the highest forecasted price for STAA Staar Surgical Company?
The highest price target for STAA is $28.00 from Thomas Stephan at Stifel, which represents a 16.7% increase from the current price of $23.99.
What is the lowest forecasted price for STAA Staar Surgical Company?
The lowest price target for STAA is $16.00 from Matt O'Brien at Piper Sandler, which represents a -33.3% decrease from the current price of $23.99.
What is the overall STAA consensus from analysts for Staar Surgical Company?
The overall analyst consensus for STAA is neutral. Out of 17 Wall Street analysts, 1 rate it as Buy, 9 as Hold, and 0 as Sell, with a median price target of $28.00.
How accurate are STAA stock price projections?
Stock price projections, including those for Staar Surgical Company, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 11, 2025 4:12 AM UTC